

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER D01/166
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U. S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/869519
INTERNATIONAL APPLICATION NO. PCT/IL99/000710	INTERNATIONAL FILING DATE December 30, 1999	PRIORITY DATE CLAIMED December 30, 1998
TITLE OF INVENTION DISPERSIBLE CONCENTRATE FOR THE DELIVERY OF CYCLOSPRIN		
APPLICANT(S) FOR DO/EO/US ABRAHAM J. DOMB		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to being national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: **Copy of International Application as published**

U. S. APPLICATION NO. (If known, see 37 CFR 1.5)

097/869519

INTERNATIONAL APPLICATION NO.
PCT/IL99/000710ATTORNEY'S DOCKET NUMBER
D01/16617. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5):**

Neither international preliminary examination fee (37 CFR 1.482)
Nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
And International Search Report not prepared by the EPO or JPO\$970.00

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO\$840.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but
international search fee (37 CFR 1.445(a)(2)) paid to USPTO\$690.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
But all claims did not satisfy provisions of PCT Article 33(1) - (4).....\$670.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
and all claims satisfied provisions of PCT Article 33(1) - (4).....\$96.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$ 690.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30
Months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	33 -20 =	13	X \$18.00
Independent claims	2 -3 =	0	X \$78.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00
TOTAL OF ABOVE CALCULATIONS =			\$ 924.00
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).			
SUBTOTAL =			\$ 924.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 Months from the earliest claimed priority date (37 CFR 1.492(f)).			\$
TOTAL NATIONAL FEE =			\$ 924.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be Accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$
TOTAL FEES ENCLOSED =			\$ 924.00
			Amount to be refunded: \$
			Charged: \$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	33 -20 =	13	X \$18.00
Independent claims	2 -3 =	0	X \$78.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00
TOTAL OF ABOVE CALCULATIONS =			\$ 924.00
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).			
SUBTOTAL =			\$ 924.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 Months from the earliest claimed priority date (37 CFR 1.492(f)).			\$
TOTAL NATIONAL FEE =			\$ 924.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be Accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$
TOTAL FEES ENCLOSED =			\$ 924.00
			Amount to be refunded: \$
			Charged: \$

CALCULATIONS PTO USE ONLYa. ☒ A check in the amount of \$ 924.00 to cover the above fees is enclosed.b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.c. ☐ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. _____. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b))
must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

DR. D. GRAESER LTD.
C/O THE POLKINGHORNS
9003 FLORIN WAY
UPPER MARLBORO
MARYLAND 20772
USA

SIGNATURE

D'VORAH GRAESER

NAME

40.000

REGISTRATION NUMBER

JUN 25, 2001

DISPERSIBLE CONCENTRATE FOR THE DELIVERY OF CYCLOSPORINFIELD AND BACKGROUND OF THE INVENTION

The present invention is of a dispersible concentrate preparation for the delivery of
5 cyclosporin, and in particular, of a dispersible concentrate preparation which provides a delivery
system with high bioavailability of cyclosporin and related substances.

Many dispersion systems are currently in use as, or being explored for use as, carriers of
substances, particularly biologically active compounds. These systems are designed to protect the
substance from the environment during delivery and to provide a controlled release of the
10 substance to a targeted area. In some cases, the goal is to target specific sites in the body using
the dispersion. In other cases, the goal is to prepare a drug carrier system that acts as a reservoir
at the site of injection.

Dispersion systems used for pharmaceutical and cosmetic formulations can be
categorized as either suspensions or emulsions. Suspensions are defined as solid particles ranging
15 in size from a few nanometers up to hundreds of microns, dispersed in an aqueous or nonaqueous
medium using suspending agents. Solid particles include microspheres, microcapsules, and
nanospheres.

Emulsions can be defined as dispersions of one liquid in another, stabilized by an
interfacial film of emulsifiers such as surfactants and lipids. Despite their long history, emulsions
20 are used less often today than many other dosage forms due to the inherent instability. Emulsion
formulations include water in oil and oil in water emulsions, multiple water/oil/water emulsions,
microemulsions, microdroplets, and liposomes.

A microemulsion is a transparent or substantially transparent emulsion which is formed
spontaneously or substantially spontaneously when its components are brought into contact.
25 Microemulsions are thermodynamically stable and contain dispersed particles or droplets of a
size less than about 200 nm. Generally microemulsions feature droplets or particles having a
mean diameter of less than about 150 nm. These particles may be spherical, although other
structures are feasible, such as liquid crystals with lamellar, hexagonal or isotropic symmetries.
Microemulsions are usually stable over periods in excess of 24 hours.


30 Microemulsions can also be used as a "microemulsion preconcentrate", defined herein as
a composition which spontaneously forms a microemulsion in an aqueous medium, for example

in water, upon dilution, or in the gastric juices after oral application. Dilution of the microemulsion in water can be for example from about 1:1 fold to about 1:10 fold dilution.

As noted above, while emulsion based delivery systems are useful for certain applications, the delivering vesicles are subject to physical rupture because of the delicate nature of the liquid/membrane/liquid structure. Emulsion based delivery systems also have relatively short release times. Further, it is difficult to isolate emulsion based vesicles from the aqueous media used for storage for subsequent reconstitution.


In spite of these difficulties, microemulsions have been the only successful delivery systems for certain types of pharmaceutical compounds, particularly compounds such as members of the cyclosporin class, which are cyclic oligopeptides. The cyclosporin class includes substances having pharmaceutical utility, for example as immunosuppressive agents, anti-parasitic agents and agents for the reversal of multi-drug resistance, as known and described in the art. Examples of such cyclosporins include, but are not limited to, Cyclosporin A (also known as and referred to herein as "Ciclosporin"), Cyclosporin G, [O-(2-hydroxyethyl)-(D)Ser]²-Ciclosporin and [3'-deshydroxy-3'-ket-MeBmt]¹-[Val]²-Ciclosporin.

The first of the cyclosporins to be isolated was the naturally occurring fungal metabolite Cyclosporin (Cyclosporine). Cyclosporin is the cyclosporin of formula (I):



wherein -MeBmt- represents the N-methyl-(4R)-4-but-2E-en-1-yl-4-methyl-(L)threonyl residue of formula (II):

3



in which -x-y- is -CH=CH- (trans). Ciclosporin is well known as an immunosuppressive agent. In addition, Ciclosporin is being examined for the treatment of autoimmune and inflammatory diseases.

Since the original discovery of Ciclosporin, a wide variety of naturally occurring cyclosporins have been isolated and identified, and many further non-natural cyclosporins have been prepared by total- or semi-synthetic means or by the application of modified culture techniques. The class comprised by the cyclosporins now includes, for example, the naturally occurring cyclosporins A through Z [c.f. Traber *et al.*, *Helv. Chim. Acta.* **60**: 1247-1255, 1977; Traber *et al.*, *Helv. Chim. Acta.* **65**: 1655-1667, 1982; Kobel *et al.*, *Europ. J. App. Microbio. and Biotech.*, **14**: 273-240 (1982); and von Wartburg *et al.*, *Progress in Allergy*, **38**: 28-45 (1986)], as well as various non-natural cyclosporin derivatives and artificial or synthetic cyclosporins including: the so-called dihydro-cyclosporins, in which the moiety -x-y- of the -MeBmt- residue in Formula (II) above is saturated to give -x-y- of -CH₂-CH₂-; derivatized cyclosporins (e.g. in which a further substituent is introduced at the α -carbon atom of the sarcosyl residue at the 3-position of the cyclosporin molecule); cyclosporins in which the -MeBmt- residue is present in isomeric form (e.g. in which the configuration across positions 6' and 7' of the -MeBmt- residue is *cis* rather than *trans*); and cyclosporins in which variant amino acids are incorporated at specific positions within the peptide sequence. Many of these members of the cyclosporin class exhibit pharmaceutical utility which may be comparable to that of Ciclosporin.

Unfortunately, many difficulties have been encountered in the effective administration of Ciclosporin. difficulties which appear to be inherent in the nature of the members of the

cyclosporin class. Cyclosporins are characteristically highly hydrophobic, and thus require a lipophilic carrier. The selection of a suitable carrier is particularly critical for the administration of cyclosporins, as the bioavailability of these compounds is known in the art to be highly variable, depending upon the properties of the carrier. Furthermore, these compounds are known to have bioavailability which may vary significantly between individuals. Such variation is particularly dangerous given the side effects of cyclosporins, such as nephrotoxicity. Thus, the suitable carrier must provide good bioavailability of cyclosporins which is substantially consistent between individuals.

As noted previously, cyclosporins may be administered with a microemulsion carrier. This carrier generally contains a hydrophilic solvent, such as liquid PEG200-600, ethylene or propylene glycol, ethanol or propanol, glycerin, water soluble fatty acid C6-C18 esters of sucrose, dimethylisorbide, ethyl-acetate, glycofurol (fatty acid derivative of a cyclic polyol), PEG derivatives of tocopherol, or PEG-fatty acid esters; a surfactant, such as Tween 20, various PEG (polyethylene glycol) derivatives or phospholipids; a water insoluble oil such as corn oil and other oils from plants and mixtures of oils; and Cremophor™ and similar PEG derivatives of castor oil or other fats which are used as an amphiphilic solvent, emulsifier, surfactant and so forth. Unfortunately, none of these background art formulations provides high bioavailability for cyclosporin.

The currently commercially available formulation is disclosed in U.S. Patent No. 5,342,625 to Sandoz A.G. This formulation includes a hydrophilic phase, a lipophilic phase and a surfactant. The hydrophilic phase could be a C₁₋₅ alkyl di- or partial-ether of a mono- or poly-oxy-C₂₋₁₂alkanediol, for example.

PCT Application No. WO 96/13273 to Sandoz describes compositions for cyclosporin and other macrolide drugs such as Rapamycin, containing a hydrophilic phase which includes dimethylisorbide and/or a lower alkyl alkanoic ester, a lipophilic phase and a surfactant. The particle size after dispersion can be 200 nm but is preferably 100 nm or less. The hydrophilic phase is PEG, propylene glycol and glycofurol or dimethylisorbide (a bicyclic ether). The bioavailability of a composition containing cyclosporin and the carrier is not disclosed.

PCT Application No. WO 97/19692, also to Sandoz, describes compositions which are based on PEG-derivatives of saturated hydroxy fatty acids such as PEG-hydroxystearate and a low alcohol such as ethanol or propylene glycol. Again, the bioavailability of such a composition is not disclosed.

PCT Application No. WO 98/33512 to Novartis describes compositions for oral administration of cyclosporin which do not contain oil. Instead, these compositions contain a surfactant with HLB 10 or higher and a hydrophilic phase which is polyethylene glycol and/or a lower alcohol (not more than 12%). The formulations are preconcentrates which provide a particle size of 10 to 150 nm upon dispersion. The disclosed advantage of these compositions is their ability to be stably contained within a hard capsule. However, no specific data is disclosed related to the bioavailability of cyclosporin with this composition. As noted above, the bioavailability of cyclosporin is known to be highly variable, depending upon the carrier.

PCT Application No. WO 97/04795 to POLI Industria describes compositions that must contain one polymer, linear or crosslinked PEG and poly(acrylic) or mixtures thereof and monoesters of fatty acids with a short alcohol. Again, the bioavailability of such a composition is not disclosed.

U.S. Patent No. 5,756,450 to Novartis describes solid formulations for cyclosporin composed of a water soluble monoester of a fatty acid C6-C18 with a polyol, for example a saccharide such as Saccharose monolaurate or raffinose monolaurate. This solvent can be used in combination with other water soluble solvents including PEG, ethanol, ethylene glycol and glycerin. The examples describe solid solutions (powder) of Cyclosporin in saccharose monooleate which is completely soluble in water. Again, the bioavailability of such a composition is not disclosed.

U.S. Patent Nos. 5,603,951 and 5,639,474 to Hanmi Pham. describe compositions of dimethylisorbide as a cosurfactant and a primary alcohol, medium chain triglycerides and a surfactant having a HLB value of 10 to 17 such as Tween 20, formulated in soft gelatin capsule. The particle size is about 100 nm. Again, the bioavailability of such a composition is not disclosed.

U.S. Patent No. 5,583,105 to Biogel describes cyclosporin formulations composed of PEG esters of tocopherol and a lipophilic solvent, an amphiphilic solvent and ethanol. Again, the bioavailability of such a composition is not disclosed.

U.S. Patent No. 5,614,491 to Dr. Rentschler GmbH, describes formulations of PEG fatty acid monoesters as emulsifying agent and a polyol as solvent. U.S. Patent No. 5,798,333 to Sherman describes formulations composed of Tocophersolan and a polyhydric alcohol. Tocophersolan is a water soluble surfactant which dissolves cyclosporin only at a 7:1 ratio.

U.S. Patent No. 5,827,822 to Sangstat describes formulations of alcohol and a PEG surfactant forming particle size between 200 and 400 nm.

European Patent Application No. EP 0760237 A1 to Cipla describes a composition containing: vegetable oil triglycerides (castor, peanut, or coconut oil), phospholipid, a surfactant (Tween 20, polyoxyl-40-hydrogenated castor oil), and a hydrophilic solvent, propylene glycol. Again, the bioavailability of cyclosporin administered with such a composition is not disclosed.

None of these disclosed background art carrier formulations features a hydrophilic solvent which is a lower alkyl ester of hydroxyalkanoic acid, such as ethyl lactate or N-methyl pyrrolidone. Moreover, none of these disclosed background art carrier formulations features a combination of a surfactant with high HLB and a surfactant with low HLB. Furthermore, none of these background art carrier formulations is disclosed as having high bioavailability. Thus, the background art carrier formulations do not appear to possess the advantageous high bioavailability of the present invention, as described in greater detail below.

There is thus an unmet need for, and it would be useful to have, a composition for the administration of cyclosporins, particularly for oral administration, which would provide a high bioavailability, and which would preferably contain a hydrophilic solvent which is a lower alkyl ester of hydroxyalkanoic acid, and a surfactant which is preferably a combination of a surfactant with high HLB and a surfactant with low HLB.

SUMMARY OF THE INVENTION

The present invention is of a novel formulation for the administration of a cyclosporin. This formulation features a hydrophilic solvent which is characterized by being a lower alkyl ester of hydroxyalkanoic acid; and a surfactant, preferably a combination of a surfactant with a high HLB (hydrophilic/lipophilic balance) of at least about 8 and a surfactant with a low HLB of less than about 5.

Other ingredients are optional, such as a fatty acid ester such as tricaprin, a phospholipid, and an ethoxylated fat such as Cremophor™ or another similar substance.

The preferred mean diameter of the particle of the resultant formulation is less than about 100 nm, more preferably less than about 60 nm, and most preferably from about 5 nm to about 50 nm.

Hereinafter, the term "dispersible concentrate" includes those compositions featuring droplets or particles having a mean diameter of less than about 150 nm. Hereinafter, the term

“nanodispersion preconcentrate” refers to a composition which spontaneously forms a nanodispersion in an aqueous medium, for example in water upon dilution, or in the gastric juices after oral application. Dilution of the nanodispersion preconcentrate in water can be for example from about 1:1 fold to about 1:10 fold dilution.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention is herein described, by way of example only, with reference to the accompanying drawings, wherein:

FIG. 1 is a graph of cyclosporin blood concentration after oral administration of 4 capsules of 50 mg cyclosporin in a first dispersible concentrate formulation of the invention;

FIG. 2 is a graph of cyclosporin blood concentration after oral administration of 2 capsules of 100 mg cyclosporin in a second dispersible concentrate formulation of the invention; and

FIG. 3 is a graph of cyclosporin blood concentration after oral administration of formulations according to the present invention in order to demonstrate the effect of particle size on bioavailability.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is of a novel formulation for the administration of a cyclosporin. This formulation features a hydrophilic solvent which is characterized by being a lower alkyl ester of hydroxyalkanoic acid; and a surfactant, preferably a combination of a surfactant with a high HLB (hydrophilic/lipophilic balance) of at least about 8 and a surfactant with a low HLB of less than about 5. The hydrophilic solvent is preferably ethyl lactate.

Other ingredients are optional, such as a fatty acid ester such as tricaprln, a phospholipid, and an ethoxylated fat such as Cremophor™ or another similar substance. Optionally, a sufficient amount of the ethoxylated fat such as Cremophor™ is substituted for the surfactant.

Another advantage of the present invention is that solid fats, such as tricaprln, are suitable for use with the formulations of the present invention and may optionally be incorporated therein. Hereinafter, the terms “solid fat” and “liquid fat” refer to fats which are solid or liquid, respectively, at room temperature.

Preferably, the composition of the present invention does not include an alcohol such as ethanol.

The preferred particle size of the resultant formulation is less than about 100 nm, more preferably less than about 60 nm, and most preferably from about 5 nm to about 50 nm. In fact,
5 as described in greater detail below, the resultant formulation must have a particle size of less than about 100 nm in order to be suitable for the administration of cyclosporin.

As described in greater detail below, the combination of these components has unexpectedly been shown to provide higher bioavailability than had been previously shown for formulations of cyclosporin. Furthermore, the formulations of the present invention have the
10 advantage of not requiring stabilizers, such as anti-oxidants, in order to obtain good stability characteristics. Without wishing to be limited to a single mechanism, it is hypothesized that the excellent stability of the formulations of the present invention is due to the use of hydrophilic solvents such as ethyl lactate.

Ethyl lactate, and other members of this family of solvents, have unexpectedly good
15 properties for such a formulation as the formulations of the present invention. For example, ethyl lactate is miscible in both organic and inorganic solvents, since it is more hydrophobic than ethanol. Ethyl lactate has higher storage stability than ethanol. Ethanol is a highly volatile solvent, with correspondingly lower storage stability, such that the use of ethanol in the currently available background art formulations is a clear disadvantage of these formulations.

Furthermore, these background art formulations require a combination of ethanol and propylene glycol in order to stabilize the alcohol, which is another disadvantage of incorporating ethanol into a formulation, a disadvantage which is overcome by the formulations of the present invention.
20

The present invention may be more readily understood with reference to the following
25 illustrative examples. It should be noted that reference is made generally to "cyclosporin", indicating any member of the cyclosporin class having pharmaceutical efficacy. The particularly preferred member of the cyclosporin class is Cyclosporin (Cyclosporin A). The preparation of the microemulsion compositions of the present invention is described first with reference to the following general description and then with reference to
30 the following non-limiting examples of the preparation and application of the compositions of the present invention.

Hydrophilic Solvent

First, as noted previously, a suitable hydrophilic organic solvent must be selected. The solvent is preferably selected from the family of lower alkyl esters of hydroxyalkanoic acid or from the family of lower alkyl esters of N-alkyl pyrrolidone. Hereinafter, the term "lower alkyl" includes C₁ to C₄, for example ethyl. The preferred hydrophilic solvents of the present invention are C1-4 alkyl-hydroxy alkanoic acid ester, or N-C1-4 alkyl pyrrolidone. More preferably, the hydrophilic solvent is selected from the group consisting of ethyl lactate or N-methyl pyrrolidone.

Ethyl lactate (2-hydroxypropanoic acid ethyl ester), is a colorless liquid which is miscible with water, alcohol and ether. Ethyl lactate is considered to be suitable for human administration, with an LD₅₀ which was higher than 5 g/kg in mice when given an oral dose. N-methyl pyrrolidone is a colorless liquid which is miscible with water and organic solvents, and is also considered to be safe for human administration. N-methyl pyrrolidone is used in the clinic as a solvent for a polymeric *in situ* implant to treat gingivitis.

Alternatively and more preferably, a combination of a solvent selected from the family of lower alkyl esters of hydroxyalkanoic acid and a solvent selected from the family of lower alkyl esters of N-alkyl pyrrolidone is employed. Optionally, any of these solvents can be combined with other hydrophilic organic solvents such as ethylene glycol, glycofurol or PEG 400. These hydrophilic solvents have not been previously taught or suggested as being suitable for cyclosporins.

Surfactant

Second, a suitable surfactant is preferably selected, although optionally, a sufficient amount of an ethoxylated fat such as Cremophor™ is substituted for the surfactant, as described in greater detail below.

If a surfactant is used, the surfactant is preferably a combination of a surfactant with a high HLB (hydrophilic/lipophilic balance) of at least about 8 and a surfactant with a low HLB of less than about 5. The term "HLB" refers to the hydrophilic/lipophilic balance of a surfactant. A surfactant with high HLB is hydrophilic, while a surfactant with low HLB is hydrophobic.

Therefore, the combination of a surfactant with high HLB and a surfactant with low HLB, as is preferred for the compositions of the present invention, is actually a combination of a hydrophilic surfactant and a hydrophobic surfactant. This combination has never been taught or suggested in

the background art as being suitable for a pharmaceutical carrier for cyclosporins. Where the HLB of the surfactant has been specified in the background art, it has been given in the range of 8 to 20, which is clearly different from the combination of surfactants taught herein. Thus, the compositions of the present invention can be clearly differentiated from those taught in the background art on the basis of the preferred combination of a surfactant with a low HLB and a surfactant with a high HLB.

Particularly preferred combinations of these surfactants feature a large difference between the HLB of the low HLB surfactant and that of the high HLB surfactant. Therefore, one example of such a particularly preferred combination is a combination of Tween™ 20 and Span™ 80, although of course other such combinations could be also be used.

Span™ hydrophobic surfactants are a group of sorbitan fatty acid esters such as sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate and sorbitan monolaurate (Fiedler, H.P., "Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und Angrenzende Gebiete", Editio Cantor, D-7960 Aulendorf, 3rd edition, 1989, pages 1139-1140). Span™ 80 is an example of a low HLB surfactant, with an HLB of 4.3, and is sorbitan monooleate. They are commercially available from various producers, which include but are not limited to, Capital City Products, Croda Chem, ICI, Lippo Chem. and Atlas, under various commercial names: Arlacel™, Armotan™, Crill™, Emsorb™, Liposorb™, Protachem™, and Sorbester™.

Examples of suitable surfactants from this group, with HLB values given in parentheses, are as follows: Span™ 60 (4.7), Span™ 65 (2.1), Span™ 80 (4.3), Span™ 85 (1.8), Arlacel™ 83 (3.7), Arlacel™ C (3.7), Arlacel™ 85 (1.8), Arlacel™ 80 (4.3), and Arlacel™ 60 (4.7). These molecules are generally soluble in oil. They are also soluble in most organic solvents. In water they are generally insoluble but dispersible. Other low HLB surfactants include but are not limited to PEG-6 glyceryl monooleate (HLB of about 3 or 4), and propylene glycol laurate (HLB of 4).

Tween™ hydrophilic surfactants (Polysorbates) are a family of PEG sorbitan esters (polyoxyethylene-sorbitan-fatty acid esters), for example mono- and tri-lauryl, palmityl, stearyl and oleyl esters of the type known and commercially available under the trade name Tween™ (Fiedler, H.P., "Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und Angrenzende Gebiete", Editio Cantor, D-7960 Aulendorf, 3rd edition, 1989, pages 1300-1304). Tween™ 20

(polyoxyethylene(20)sorbitan monolaurate) has an HLB of 16.7. Other types of Tween™ surfactants may also be useful for the compositions of the present invention.

Tween™ surfactants are soluble in water but not in oil. The chemical structure of this family of surfactants features one, two or three short PEG chains, generally of about 5 to 20 ethylene glycol units, connected by an ester bond to sorbitan. These surfactants are produced by various companies (Croda, ICI, Sandoz, Mazer, Atlas) and may appear under various trade names, besides Tween™: Sorlate™, Monitan™, Criliet™ and so forth. Members of this family which are polysorbates 20, 21, 0, 60, 61, 65, 80 and 85 have an HLB between 11 and 16.7, and therefore would be suitable for the present invention as high HLB surfactants.

Other suitable high HLB surfactants may be obtained from manufacturers such as Gattefosse Ltd., and include but are not limited to, sucrose fatty acid esters such as saccharose monopalmitate (HLB of 15) and saccharose monostearate (HLB of 11), or PEG-32 glyceryl laurate (HLB of 14). Suitable high HLB nonionic surfactants are polyethylene glycol (PEG) n-alkanol esters of the Brij family such as Brij 35, 56, 58, 76, 78, and 99 which have an HLB in the range of 12.4 to 16.9. Brij 56 is polyoxyethylene[10] cetyl ether and is an example of such a high HLB surfactant which can be substituted for Tween™ 20 or Cremophor™. Brij™ 56 has an HLB of 12.9.

Phospholipid (optional)

Next, various optional ingredients should be selected. One example of an optional ingredient is a phospholipid. A phospholipid is a phosphorylated diacylglyceride molecule or its derivative. The parent structure is diacylglycerol phosphate, or phosphatidic acid. Phosphatidyl choline (lecithin) is the choline ester of phosphorylated diacylglyceride. Synthetic lecithin are available with acyl chain lengths ranging from 4 to 19 carbons. The preferred lecithins for biological applications are those with alkyl chain lengths in the biological range (10 to 18 carbons). Naturally occurring lecithin can be obtained from a variety of sources such as egg, bovine heart, or soy bean. Unsaturated lecithins (dioleoyl; dilinoleoyl; alpha-palmitoyl, beta oleoyl; alpha palmitoyl, beta linoleoyl; and alpha oleoyl, beta palmitoyl), dianachidonoyl lecithin (highly unsaturated and a prostaglandin precursor), and alpha palmito beta myristoyl lecithin are also available.

Certain phospholipids, such as phosphatidic acid, phosphatidyl serine,

phosphatidyl inositol, cardiolipin (diphosphatidyl glycerol), and phosphatidyl glycerol, can react with calcium in serum, causing aggregation or the binding of lipospheres to cell membranes.

These unfavorable reactions can be minimized by combining these phospholipids with non-calcium binding phospholipids such as phosphatidylcholine. Phosphatidic acid can be isolated from egg or prepared synthetically (dimyristoyl, dipalmitoyl and distearoyl derivatives are available from Calbiochem). Bovine phosphatidyl serine is also available commercially (Sigma Chemical Co., St. Louis, Mo.). Phosphatidyl inositol can be isolated from plant or bovine sources. Cardiolipin can be purified from bovine or bacterial sources. Phosphatidyl glycerol can also be purified from bacterial sources or prepared synthetically.

Phosphatidyl ethanolamine in the pure state self-aggregates in a calcium-independent fashion, and is believed to have strong tendencies to aggregate with cell membranes, should be used in combination with non-aggregating phospholipids. Phosphatidyl ethanolamine is commercially available, isolated from egg, bacteria, bovine, or plasmalogen or as the synthetic dioctadecanoyl, dioleoyl, dihexadecyl, dilauryl, dimyristoyl and dipalmitoyl derivatives.

Ethoxylated fat (optional)

Another optional ingredient is an ethoxylated fat. These ethoxylated fats may be reaction products of a natural or hydrogenated castor oil and ethylene oxide. The natural or hydrogenated castor oil may be reacted with ethylene oxide in a molar ratio of from about 1:35 to about 1:60, with optional removal of the polyethyleneglycol component from the products.

One example of a particularly preferred suitable, commercially available ethoxylated fat is Cremophor™ EL, which is one of a group of polyethyleneglycol-hydrogenated castor oils.

Other members of this group, such as Cremophor™ RH 40 and Cremophor™ RH 60, may also be suitable.

Similar or identical products which may be used are available under the trade names NIKKOL (e.g. NIKKOL HCO-40 and HCO-60), MAPEG (e.g. MAPEG CO-40h), INCROCAS (e.g. INCROCAS 40) and TAGAT (for example polyoxyethylene-glycerol-fatty acid esters such as TAGAT RH 40; and TAGAT TO, a polyoxyethylene-glycerol-trioleate having an HLB value of 11.3).

Fatty Acid Ester (optional)

Yet another optional ingredient is a fatty acid ester such as tricaprin. Tricaprin is a hydrophobic triester of glycerol and caproic acid. Tricaprin does not dissolve in water and thus remains as a component of the dispersed cyclosporin-loaded particles after dispersion in aqueous solution. Tricaprin solubilizes cyclosporin in a fatty medium which is dispersed by the hydrophilic-hydrophobic dispersing agents. Other such fatty components which are suitable as replacement for tricaprin include, but are not limited to, pure and mixed alkyl esters of fatty acids and mixtures thereof. Examples include but are not limited to ethyl esters of fatty acids such as ethylstearate and ethylpalmitate triglycerides such as trilaurin and trimyristin. Mixtures of fats include hydrogenated vegetable oils. The preferred fats are those that solubilize cyclosporin with a melting point between 25 and 37 °C, such that the resultant preconcentrate formulation forms a nanodispersion of solid particles which melt into an emulsion at body temperature.

The following specific examples illustrate various aspects of the present invention, and are not intending to be limiting in any way. For all experiments described below, unless otherwise stated, the particle size of the preconcentrate was measured with an N4-Coulter particle size analyzer, suitable for submicron particle size determination. Three drops of the preconcentrate were added to five milliliters of water. The particle size of the preconcentrate did not change when the preconcentrate was dispersed in five milliliters of 0.1N HCl solution. The member of the cyclosporin class which was used for the experiments described below was Ciclosporin (Cyclosporin A).

Example 1Effect of Solvent on Particle Size

An exemplary composition containing Ciclosporin, solvent, TRC (tricaprin), egg phospholipid (Avanti, USA), Tween™ 20, Span™ 80 and Cremophor™ was prepared with increasing amounts of ethyl lactate or N-methylpyrrolidone, as given in Table 1 (all amounts of ingredients are given in milligrams). The effect of adding increasing amounts of these ingredients to the composition of the present invention on (mean) particle size is also given in Table 1. Briefly, all compositions which contained either ethyl lactate or N-methylpyrrolidone had a particle size of less than 100 nm. The particle size decreased as the amount of either ethyl

lactate or N-methylpyrrolidone was increased. Ethyl lactate was generally more effective than N-methylpyrrolidone for providing particles of a smaller size. The addition of ethylene glycol (as in Formulation 9), propylene glycol or liquid polyethylene glycol (PEG 200-600) to the formulations containing either ethyl lactate or N-methylpyrrolidone did not increase the particle size to greater than 100 nm.

Table 1: Effect of Solvent on Particle Size

<u>Ingredient</u>	<u>Formulation Number</u>								
	1	2	3	4	5	6	7	8	9
Ciclosporin	100	100	100	100	100	100	100	100	100
ethyl lactate	0	100	200	400	0	0	100	200	200
N-methyl pyrrolidone	0	0	0	0	200	400	100	200	200
phospholipid	70	70	70	70	70	70	70	70	70
Tween 20	270	270	270	270	270	270	270	270	270
TRC	130	130	130	130	130	130	130	130	130
Span 80	100	100	100	100	100	100	100	100	100
Cremophor EL	300	300	300	300	300	300	300	300	300
particle size	189	92	42	28	82	57	88	39	31

Example 2

Effect of Surfactant on Particle Size

An exemplary composition containing Ciclosporin, egg phospholipid (95% pure from Avanti, USA), ethyl lactate as a solvent, Tween™ 20 and Cremophor™ was prepared with increasing amounts of Span™ 80, as given in Table 2 (all amounts of ingredients are given in milligrams). The effect of adding increasing amounts of Span™ 80 to the composition of the present invention on (mean) particle size is also given in Table 2. Briefly, the compositions provided a liquid solution. When dispersed in deionized water, all compositions which contained Span™ 80 had a particle size of less than 100 nm. The particle size decreased as the amount of Span™ 80 was increased.

Table 2: Effect of Surfactant on Particle Size

<u>Ingredient</u>	<u>Formulation Number</u>				
	1	2	3	4	5
Ciclosporin	100	100	100	100	100
ethyl lactate	300	300	300	300	300
phospholipid	50	50	50	50	50
Tween 20	200	200	200	200	200
Span 80	0	50	100	200	300
Cremophor EL	400	400	400	400	400
particle size	155	88	54	32	28

Example 3**Effect of Other Ingredients on Particle Size**

Different compositions containing Ciclosporin were prepared as described in Table 3 (all amounts of ingredients are given in milligrams). The effect of these ingredients on the particle size of the preconcentrate solution when dispersed in water is also given in Table 3. Briefly, compositions which had both low and high HLB surfactants (such as Tween™ or Cremophor™ and Span™) had a particle size of less than 100 nm. Tween™ and Cremophor™ can be substituted for each other as high HLB solvents (HLB>10) but a certain amount of either surfactant is required to obtain a suitable particle size, depending upon the quantities of the other components. In addition, the presence of a solvent such as ethyl lactate is required. A lipid such as tricaprins is clearly preferred. The presence of a phospholipid is also preferred to obtain a particle size in the range of 30 nm, although the particle size remained below 100 nm even without the phospholipid, as for Formulation 3, in which no phospholipid was added but the particle size was 95 nm.

Table 3: Effect of Other Ingredients on Particle Size

<u>Ingredient</u>	<u>Formulation Number</u>									
	1	2	3	4	5	6	7	8	9	10
Ciclosporin	100	100	100	100	100	100	100	100	100	100
ethyl lactate	400	200	400	400	400	400	400	600	400	400
phospholipid	100	100	0	100	100	100	100	100	100	100
Tween 20	200	200	200	200	0	200	200	200	400	0
TRC	200	200	200	200	200	0	200	200	200	200
Span 80	200	200	200	0	200	200	200	200	200	200
Cremophor EL	200	200	200	200	200	200	0	200	0	400
particle size	28	30	95	187	182	230	340	32	78	64

Example 4Effect of Low HLB Surfactant on Particle Size

5 Compositions containing Span™ 80 as an example of a low HLB surfactant was prepared by dissolving the components into a liquid at room temperature. The (mean) particle size is given in Table 4 (all amounts of ingredients are given in milligrams). Briefly, tricaprin could be substituted with other triglycerides and oil mixtures such as medium chain triglycerides (MCT). Brij is a group of polyoxyethylene alcohol ethers. Brij 56 is polyoxyethylene[10] cetyl ether and

10 is a high HLB surfactant which can be substituted for Tween™ 20 or Cremophor™. Brij™ 56 has an HLB of 12.9.

Table 4: Effect of High HLB Surfactant on Particle Size

<u>Ingredient</u>	<u>Formulation Number</u>						
	1	2	3	4	5	6	7
Ciclosporin	100	100	100	100	100	100	100
ethyl lactate	400	400	400	400	0	400	400
N-methyl pyrrolidone	0	0	0	0	400	0	0
phospholipid	70	70	70	70	70	70	70
Span 80	270	0	270	270	270	270	270
Tween 20	0	270	270	0	0	0	270
Brij 56	0	0	0	270	270	270	270
TRC	130	130	130	130	130	0	130
MCT	0	0	0	0	0	130	0
Cremophor EL	400	400	400	400	400	400	0
particle size	56	197	25	29	55	48	83

Example 5

5

Selection of a First Preferred Formulation

Two of the preferred formulations, 5 and 8, were selected from the formulations in Table 5 (all amounts of ingredients are given in milligrams). An additional preferred formulation is given in Example 10. These formulations had the smallest particle size (in the range of about 30 nm).

Table 5: Preferred Formulations

<u>Ingredient</u>	<u>Formulation Number</u>							
	1	2	3	4	5	6	7	8
Ciclosporin	100	200	100	100	100	100	100	100
ethyl lactate	400	800	400	400	400	400	400	400
phospholipid	70	140	70	70	100	70	70	100
Span 80	270	540	270	270	270	150	200	200
Tween 20	270	540	270	270	270	150	200	200
TRC	130	260	130	130	200	130	130	200
Cremophor EL	400	800	100	200	0	0	0	0
Cremophor HR	40	0	0	0	200	200	200	200
particle size	41	55	68	42	23	75	52	29

Example 6**Storage Stability of Preferred Formulation**

5 One composition was prepared at two different total quantities (all amounts of ingredients are given in milligrams). At the first volume, the composition contained 400 Ciclosporin, 1600 ethyl lactate, 400 phospholipid, 800 Span™ 80, 800 Tween™ 20, 800 TRC and 800 Cremophor™ HR. At the second volume, the amount of each ingredient was ten-fold larger. Both

10 compositions were easily prepared by dissolving all components to a liquid solution by mixing with mild heating (about 40 °C). Preferably, the phospholipid was first dissolved in ethyl lactate, and then all other components were added with continuous mixing, apart from Ciclosporin which was added last. The mean particle size of the composition was measured after dispersion of

15 different amounts of the composition in deionized water by using the light scattering technique with a Coulter N4 particle size analyzer. Both volumes of the composition had a particle size below 30 nm which is preferred. This composition was used for human studies, as described in greater detail below.

Table 6: Dispersion in Water

	<u>Drops of composition/ml of water</u>			
<u>particle size</u>	<u>3 drops/5 ml</u>	<u>3 drops/5 ml</u>	<u>10 drops/5 ml</u>	<u>20 drops/5 ml</u>
first test	37	22	18	18
second test	22	21	17	17
third test	19	24	18	17

The stability of the composition was tested by loading doses of 50 mg of Ciclosporin into hard gelatin capsules (size 00) or in glass containers, and then storing the composition at room temperature (25 °C) or at refrigeration (4 °C). The particle size and the Ciclosporin content was determined after 3 and 6 months of storage. All samples were found to have a particle size in the range between 17.2 and 32.6 at any dispersion range (3 to 20 drops per 5 ml). As calculated from the peak size after analysis by HPLC (high pressure liquid chromatography), the Ciclosporin content for all stored formulations was in the range of 95 to 104% of the initial concentration.

Example 7

Analysis of Preferred Formulation

The composition of Example 6 was prepared 5 times independently for 400 mg Ciclosporin. The particle size, Ciclosporin content, the morphology of the formed particles and the melting point of the particles was determined. The bioactivity of the Ciclosporin formulation on T-cells was also determined.

The particle size of all formulations ranged between 18 to 29 nm when dispersed in deionized water or 0.1 N HCl solution. The particles were viewed by Transmission Electron Microscope (TEM) at high magnification. Spherical particles with a narrow size distribution in the range of 30 nm were observed. The melting point of the particles was determined by differential scanning calorimeter (DSC) and was found to be in a temperature range of from 30 to 35 °C. The composition was highly effective at inhibiting the activity of T-cells. The results clearly indicate the superior stability, reproducibility and efficacy of the preferred formulation.

Example 8Effect of Ciclosporin Content on Preferred Formulation

The composition of Example 6 was prepared with increasing amounts of Ciclosporin and the particle size was determined. The results, shown in Table 7, are an average of five independent experiments (all amounts of ingredients are given in milligrams). The particle size increases as the amount of Ciclosporin is increased above 60 mg in this composition.

Table 7: Effect of Ciclosporin

<u>Ingredient</u>	<u>Formulation Number</u>					
	1	2	3	4	5	6
Ciclosporin	50	55	60	65	70	75
ethyl lactate	200	200	200	200	200	200
phospholipid	50	50	50	50	50	50
Span 80	100	100	100	100	100	100
Tween 20	100	100	100	100	100	100
TRC	100	100	100	100	100	100
Cremophor HR	100	100	100	100	100	100
particle size	28	31	30	56	88	92

The composition containing 50 mg of Ciclosporin was bottled. The bottles were stored at room temperature or at 37 °C and the particle size was determined. The results are shown in Table 8.

Table 8: Stability of Ciclosporin Compositions

<u>Day No.</u>	<u>Particle size (room temp)</u>	<u>Particle size (37 °C; nm)</u>
0	30	30
7	67	24
13	39	26
16	65	33
42	59	33
52	31	28
4.3 months	20.9	17.1
7 months	29.2	33.7
7.6 months	26.4	27.5
9 months	29.8	31.2

Example 9Pharmacokinetic Human Studies

A randomized pilot pharmacokinetic study was undertaken to investigate the pharmacokinetic performance of the composition of the present invention, when compared to the standard commercially available formulation for Ciclosporin (Sandimmune Neoral™, Sandoz A.G.). The formulation of the present invention was tested in capsules containing 50 mg of Ciclosporin. The standard composition was tested with soft gelatin capsules containing 100 mg of Ciclosporin. Four capsules of the formulation of the present invention, containing 50 mg of Ciclosporin per capsule, or two capsules of the commercially available formulation, containing 100 mg of Ciclosporin per capsule, were orally administered to six fasting volunteers, for a total dosage of 200 mg of Ciclosporin. Blood samples were then drawn as follows: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 9, 12, 15 and 24 hours post administration. A one-week washout period separated the two study periods. Plasma concentrations of Ciclosporin were determined by using a standard Tdx method used for monitoring patients receiving Ciclosporin. A curve of concentration vs. time was constructed for each volunteer for each period, as shown in Figure 1 and described in greater detail below. The observed maximal concentration was recorded as C_{max} and the area under the curve. AUC₀₋₂₄ was calculated for each volunteer.

The following formulation of the present invention was studied:

<u>Ingredient</u>	<u>Weight per capsule (mg)</u>	<u>Total weight (g)</u>
Ciclosporin	50	0.25
ethyl lactate	200	0.100
Egg phosphatidylcholine	50	0.25
Span 80	100	0.050
Tween 20	100	0.050
TRC	100	0.050
Cremophor HR	100	0.050
total:	700	0.350

The composition was prepared as follows. Ciclosporin, egg phosphatidylcholine and tricaprin were dissolved in a solution of ethyl lactate and Tween™ 20 by mixing in a beaker at room temperature. The other ingredients were added and mixed to form a clear yellowish liquid. The clear liquid solution (0.350 g) was placed into 500 hard gelatin capsules (size 00). About 10 capsules were taken for particle size determination and Ciclosporin content. Each capsule contained 700 mg solution (weight range: 665-735 mg) with the corresponding amount of Ciclosporin (47.5 to 52.5 mg/capsule). The particle size of the formulation after dispersion of the contents of one capsule in 10 ml of 0.1 N HCl solution or in deionized water was determined with light scattering by using the N4 particle size analyzer (Coulter). The almost clear dispersion had an average particle size of 28 nm.

The results of the test on human volunteers are shown in Table 9 below.

Table 9: Test on Human Subjects

<u>Formulation</u>	<u>AUC (ng x hour/ml)</u>	<u>Cmax (ng/ml)</u>	<u>Tmax (hours)</u>
present invention (n=6)	5555 ± 842 (4771 - 7147)	1328 ± 216 (990 - 1591)	1.67 ± 0.28 (1 - 3)
standard (n=4)	5221 ± 2200 (2806 - 7784)	1100 ± 259 (790 - 1405)	1.88 ± 0.24 (1.5 - 2.5)

The presented values for all pharmacokinetic parameters are mean \pm S.D. and the values in parentheses are the range. The number of volunteers participating in the study is given as n . The average blood levels are shown in Figure 1. Figure 1 is a graph of Ciclosporin blood concentration after oral administration of 4 capsules of 50 mg Ciclosporin in the dispersible concentrate formulation of the invention. The formulation included 50 mg Ciclosporin, 200 mg ethyl lactate, 50 mg egg phospholipid, 100 mg Tween™ 20, 100 mg TRC, 100 mg Span™ 80, and 100 mg Cremophor™, for a resultant particle size after dispersion of 28 nm. As a reference, two Sandimmun Neoral™ (Sandoz) capsules, containing 100 mg Ciclosporin total, were administered as a reference. The results shown in Figure 1 are an average of $n=6$ for the formulation of the present invention and $n=4$ for the commercially available formulation, Sandimmun Neoral™ (Sandoz).

This human study clearly indicates the efficacy of the formulation of the present invention as compared to the best commercially available formulation, Sandimmun Neoral™ (Sandoz). The formulation of the present invention is clearly superior to this commercially available formulation as it provided a higher Cmax and AUC, with a significantly narrower standard deviation, indicating a lesser degree of variation between individual subjects.

Example 10

Pharmacokinetic Human Studies

for a Second Preferred Composition

A randomized pilot pharmacokinetic study was undertaken to investigate the pharmacokinetic performance of a second preferred composition of the present invention, when compared to the standard commercially available formulation for Ciclosporin (Sandimmune Neoral™, Sandoz A.G.). This second preferred formulation is a concentrated formulation with a higher load of cyclosporin as compared to the formulation of Example 9, containing about twenty percent more cyclosporin.

The following formulation of the present invention was studied:

<u>Ingredient</u>	<u>Weight per capsule (mg)</u>	<u>Total weight (Kg)</u>
Ciclosporin	100	1
ethyl lactate	332	3.32
lecithin (soy phospholipid)	84	0.84
sorbitan monooleate (Span 80)	168	16.8
polysorbate 20 (Tween 20)	168	16.8
Cremophor RH 40	168	16.8
triglyceride (tricaprin)	168	16.8
total:	1188	11.88

The composition was prepared as for the composition of Example 9. The particle size of the formulation after dispersion of the contents of one capsule in 10 ml of 0.1 N HCl solution or in deionized water was determined using the N4 particle size analyzer (Coulter). The almost clear dispersion had an average particle size of 25-50 nm.

This second preferred formulation of the present invention was tested in human volunteers with soft gelatin capsules containing 100 mg of Ciclosporin. The standard composition was tested with soft gelatin capsules containing 100 mg Ciclosporin. Two capsules of the formulation of the present invention, containing 100 mg of Ciclosporin per capsule, or two capsules of the commercially available formulation, containing 100 mg of Ciclosporin per capsule, were orally administered to twelve fasting volunteers, for a total dosage of 200 mg of Ciclosporin in twelve volunteers. Blood samples were then drawn as follows: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 9, 12, 15 and 24 hours post administration. A one-week washout period separated the two study periods. Plasma concentrations of Ciclosporin were determined by using a standard TDX method used for monitoring patients receiving Ciclosporin. A curve of concentration vs. time was constructed for each volunteer for each period, as shown in Figure 2 and described in greater detail below. The observed maximal concentration was recorded as C_{max}, the time of observing this concentration was recorded as T_{max}, and the area under the curve, AUC, was calculated for each volunteer.

The presented ratios of AUC and Cmax are geometric means of the individual ratios, after being calculated both directly and through logarithmic transformation (multiplicative model), according to preferred methods for determining pharmacokinetics. The 90% parametric (ANOVA) Confidence Intervals were computed for all ratios.

5 The results of the test on human volunteers are shown in Table 10 below.

Table 10: Test on Human Subjects

<u>Formulation</u>	<u>AUC (ng x hour/ml)</u>	<u>Cmax (ng/ml)</u>	<u>Tmax (hours)</u>
present invention (n=12)	5511.17 \pm 1455.74 (3108.43 - 7622.71)	1265.17 \pm 262.94 (733.8 - 1779.4)	6.00 \pm 1.60 (4 - 8)
standard (n=12)	5552.06 \pm 984.9 (3094.14 - 6596.89)	1281.51 \pm 323.11 (777 - 1881)	7.13 \pm 3.04 (4 - 12)
ratio (90% ANOVA CI)	0.97 (0.89 - 1.06)	1.00 (0.92 - 1.08)	
difference (range)			-0.25 \pm 0.40 (-1.0 - 0.5)

10 The presented values for all pharmacokinetic parameters are mean \pm S.D. and the values in parentheses are the range. The number of volunteers participating in the study is given as *n*. The ratio is the geometric means of the ratios for AUC and Cmax as calculated directly or through logarithmic transformation, as previously described. The difference is the mean result and range of Tmax.

15 The average blood levels are shown in Figure 2. Figure 2 is a graph of Ciclosporin blood concentration after oral administration of 2 capsules of 100 mg Ciclosporin in the second preferred dispersible concentrate formulation of the invention. Two Sandimmun Neoral™ (Sandoz) capsules, containing 100 mg Ciclosporin total, were administered as a reference. The results shown in Figure 2 are an average of *n*=12 for the formulation of the present invention and for the commercially available formulation, Sandimmun Neoral™ (Sandoz).

20 This human study clearly indicates the efficacy of the formulation of the present invention as compared to the best commercially available formulation, Sandimmun Neoral™ (Sandoz). The formulation of the present invention is clearly bioequivalent to this commercially available formulation as the extent and rate of absorption were similar.

In particular, the AUC values, showing the extent of absorption, had a ratio of 0.97 with a 90% ANOVA confidence interval (CI) of 0.89-1.06, which supports the bioequivalence of these formulations. Similarly, the Cmax values, showing the rate of absorption, had a ratio of 1.00, with a 90% ANOVA confidence interval of 0.92-1.08, which also supports the bioequivalence of these formulations. The rate of absorption as shown by the Tmax values also supports bioequivalence, as there was only a difference of -0.25 hours between the Tmax values of these formulations, with a range of -1.0 to 0.5 hours. Thus, clearly the second preferred formulation of the present invention was also shown to be bioequivalent to the standard, commercial available formulation, as for the composition of the present invention of Example 9.

Example 11

Effect of Fatty Acid Ester on Particle Size

An exemplary composition containing Ciclosporin, ethyl lactate, egg phospholipid (Avanti, USA), and Tween™ 20 was prepared with increasing amounts of TRC (tricaprin), as given in Tables 11A and B (all amounts of ingredients are given in milligrams). The effect of adding increasing amounts of TRC to the composition of the present invention on (mean) particle size is also given in Tables 11A and B.

Briefly, none of the compositions had a particle size of less than 100 nm. The best compositions in terms of particle size were composition number one, which featured 300 mg TRC with 100 mg phospholipid; and composition number two, which featured 200 mg TRC with 100 mg phospholipid. For the remaining compositions, in which TRC and/or phospholipid was reduced in amount or absent, had inferior particle sizes. The addition of corn oil in place of TRC caused two layers to form, due to the insolubility of corn oil in ethyl lactate, such that particle size could not be measured. Table 11A shows the effect of TRC on particle size for a single batch of each formulation, but with the particle size measured twice and with both values given separately. Table 11B shows the effect of TRC on particle size for multiple versions of formulation number two, again with the particle size measured twice and with both values given separately.

Table 11A: Effect of TRC on Particle Size

<u>Ingredient</u>	<u>Formulation Number</u>								
	1	2	3	4	5	6	7	8	9
Ciclosporin	150	150	150	150	0	150	150	150	150
ethyl lactate	600	600	600	600	600	600	600	600	600
phospholipid	100	100	100	100	100	0	0	0	0
Tween 20	400	400	400	400	400	400	400	400	600
TRC	300	200	100	0	300	300	0	0	0
corn oil	0	0	0	0	0	0	0	300	200
particle size	150	148	152	179	162	217	208	ND	ND
	170	166	166	166	160	231	257		

Table 11B: Effect of TRC on Particle Size

<u>Ingredient</u>	<u>Formulation Number</u>		
	2a	2b	2c
Ciclosporin	150	150	150
ethyl lactate	600	600	400
phospholipid	100	50	50
Tween 20	600	600	600
TRC	200	200	200
particle size	145	199	155
	172	207	272

5

Example 12Effect of Hydrophilic Solvent on Particle Size

Different compositions containing Ciclosporin were prepared as described in Tables 12A and B (all amounts of ingredients are given in milligrams). The effect of two different hydrophilic solvents, ethyl lactate and 1,2 propylene glycol, on the particle size of the preconcentrate solution when dispersed in water is also given in Table 12A; while the effect of

10

Table 12B: Effect of Hydrophilic Solvent on Particle Size

<u>Ingredient</u>	<u>Formulation Number</u>					
	1	2	3	4	5	6
Ciclosporin	100	100	100	100	100	100
ethyl lactate	400	300	0	0	400	400
glycofurol	0	0	400	0	0	0
N-methyl pyrrolidone	0	0	0	400	0	0
phospholipid	50	50	50	50	50	100
Span 80	200	200	200	200	270	200
Tween 20	200	200	200	200	270	200
TRC	200	200	200	200	200	200
Cremophor HR 40	200	200	200	200	200	200
particle size	94.8	42.1	25.2	111	86	30.1

Example 13**Effect of Ciclosporin Concentration on Particle Size**

Different compositions containing Ciclosporin were prepared as described in Table 13 (all amounts of ingredients are given in milligrams). The effect of different concentrations of Ciclosporin on the particle size of the preconcentrate solution when dispersed in water is also given in Table 13. The preferred formulation which was used for the second human bioavailability trial is formulation number two (Table 13).

Briefly, relatively high concentrations of Ciclosporin, up to 140 mg, still resulted in formulations with small particle sizes (less than 100 nm). However, the best results were obtained with concentrations of less than 100 mg of Ciclosporin.

Table 13: Effect of Ciclosporin Concentration on Particle Size

<u>Ingredient</u>	<u>Formulation Number</u>				
	1	2	3	4	5
Ciclosporin	100	120	130	140	160
ethyl lactate	400	400	400	400	400
phospholipid	100	100	100	100	100
Span 80	200	200	200	200	200
Tween 20	200	200	200	200	200
TRC	200	200	200	200	200
Cremophor RH 40	200	200	200	200	200
particle size	33.3	40.6	44	82.9	92.1

Example 14

Stability Testing of the Formulations
of the Present Invention

10 The preferred formulation according to the present invention for high loading of cyclosporin was examined for storage stability characteristics. The tested formulation is given below in Table 14A, while the results of the stability tests are given in Table 14B. Briefly, the formulation according to the present invention showed good storage stability under accelerated storage conditions.

15 In addition, these experiments demonstrate that storage stability, and the resultant effect of prolonged storage on formulations according to the present invention, can optionally be determined by measuring the particle size as previously performed. Once the particle size has been shown to be increased over a predetermined limit, the composition is then preferably determined to have destabilized beyond an acceptable limit and to no longer be suitable for administration to a subject.

The tested formulation is shown in Table 14A below, and is the preferred formulation according to the present invention for a concentrated, high load cyclosporin formulation.

Table 14A

<u>Ingredient</u>	<u>Amount (mg)</u>
Ciclosporin	120
Ethyl lactate	400
Phospholipid	100
Tween 20	200
Span 80	200
Cremophor RH 40	200
Tricaprin	200

The stability testing was performed under accelerated storage conditions of 40 °C and 75% relative humidity for up to three months, which is approximately equivalent to eighteen months of room temperature storage (Table 14B).

Table 14B. Accelerated storage

<u>Test performed</u>	<u>Specification</u>	<u>Initial Test</u>	<u>1 Month</u>	<u>2 Months</u>	<u>3 Months</u>
cyclosporin average content (percentage)	95-105 mg	98.4	98.1	100.7	97.1
particle size	100 nm	21.3	27.5	24.3	29.2

Example 15

Effect of Cyclosporin Concentration on Particle Size Distribution

A preferred formulation according to the present invention was tested for the effect of cyclosporin concentration on particle size for scaled-up batches of the composition (10,000 capsules). The amount of cyclosporin was held constant, while the remaining ingredients were adjusted in order to provide increasingly diluted formulations. The particle size was measured as previously described. Briefly, although all formulations had a suitable particle size of less than

about 100 nm, clearly the more diluted formulations had a lower, and hence more desirable, particle size. The three tested formulations and results thereof are given in Table 15 below.

Table 15

<u>Ingredient</u>	<u>formulation 1</u>	<u>formulation 2</u>	<u>formulation 3</u>
Ciclosporin	50	50	50
Tween 20	72	84	100
Span 80	72	84	100
Egg Phosphatidylcholine	36	42	50
Tricaprin	72	84	100
Cremophor RH 40	72	84	100
Ethyl lactate	144	166	200
particle size	73.6 nm	37.9 nm	32.3 nm

Example 16

Effect of Particle Size on

Bioavailability

The effect of particle size on bioavailability was tested with six formulations: the three formulations of Example 15, and three additional formulations, given in Table 16 below. Briefly, the formulations were administered to human volunteers and blood levels of cyclosporin were measured substantially as previously described. The resultant blood levels are shown in the graph of Figure 3. The relationship between each symbol of the graph and the formulation number is as follows: solid circle (30 nm particle size), formulation number 3 of Table 15; open square (75 nm), formulation number 1 of Table 15; solid triangle (160 nm), formulation number 1 of Table 16; cross (200 nm), formulation number 2 of Table 16; and open circle (400 nm), formulation number 3 of Table 16.

As shown, the greatest bioavailability is seen with the smaller particle sizes, particularly 30 nm and 75 nm. A sharp drop in bioavailability is seen with particle sizes greater than 100 nm, such as for the formulations with 160 nm, 200 nm and 400 nm particle sizes. Thus, the particle size of the formulation should be less than about 100 nm, and is preferably even smaller.

Table 16

<u>Ingredient</u>	<u>formulation 1</u>	<u>formulation 2</u>	<u>formulation 3</u>
Ciclosporin	50	50	50
Tween 80	140	100	0
Egg Phosphatidylcholine	30	100	200
Tricaprin	100	100	100
Ethyl lactate	200	200	300
particle size	160 nm	200 nm	400 nm

Example 17

Effect of Various Ingredients on the
Preferred Formulation of
the Present Invention

The effect of removing various ingredients from the formulation of the present invention was examined, in order to determinet the contribution of these individual ingredients to the overall particle size of the formulation. The concentration of at least one other ingredient was then increased in an attempt to stabilize the formulation in the absence of the missing ingredient. Table 17A shows the effect of removing Tween™ 20 and/or Span™ 80, or replacing tricaprln with corn oil. Table 17B shows the effect of Cremophor™ RH 40 alone, without Tween™ 20 or Span™ 80. The particle size was measured as previously described. Briefly, although the combination of Tween™ 20 and Span™ 80 is preferred, substituting sufficient amounts of Cremophor™ RH 40 can overcome the lack of such a surfactant combination. The particle size of the formulation was not measured with corn oil, since the corn oil separated from the other ingredients, such that particles were not formed.

Table 17A

<u>Ingredient (mg)</u>	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>
Ciclosporin	100	100	100	100
Tween 20	170	170	0	170
Span 80	170	0	170	170
Lecithin	85	85	85	85
TRC	170	170	170	0
corn oil	0	0	0	170
Cremophor RH 40	170	340	340	170
ethyl lactate	335	335	335	335
particle size (nm)	23.4 59.1	171 180	36.6 34.6	ND

Table 17B

<u>Ingredient (mg)</u>	<u>1</u>	<u>2</u>	<u>3</u>
Ciclosporin	100	100	100
Tween 20	0	0	0
Span 80	0	0	0
Lecithin	85	85	85
TRC	170	170	170
Cremophor RH 40	340	510	680
Ethyl lactate	335	335	335
particle size (nm)	199	170	37.9

5

Example 18Methods ofAdministration of Cyclosporins

10 A cyclosporin, such as Ciclosporin, can be administered to a subject in a number of ways, which are well known in the art. Hereinafter, the term "subject" refers to the human or lower animal to whom cyclosporin was administered. For example, administration may be done topically

(including opthalmically, vaginally, rectally, intranasally), orally, or parenterally, for example by intravenous drip or intraperitoneal, subcutaneous, or intramuscular injection.

Formulations for topical administration may include but are not limited to lotions, ointments, gels, creams, suppositories, drops, liquids, sprays and powders.

5 Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, sachets, capsules or tablets. Thickeners, diluents, flavorings, dispersing aids, emulsifiers or binders may be desirable. Compositions for oral administration preferably include a soft or hard gelatin capsule.

10 Formulations for parenteral administration may include but are not limited to sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.

The formulations of the present invention may optionally be administered as a dispersible concentrate or as a dispersion in aqueous liquid. Alternatively, these formulations may be lyophilized (dried) after the formation of the dispersion in aqueous liquid. The lyophilized (dried) dispersion is also optionally administered to the subject. The preferred route of administration is oral administration.

15 Dosing is dependent on the severity of the symptoms and on the responsiveness of the subject to cyclosporin. Persons of ordinary skill in the art can easily determine optimum dosages, dosing methodologies and repetition rates.

20

Example 19

Methods of Treatment with Cyclosporins

Cyclosporins are particularly noted for the treatment and prevention of organ or tissue transplant rejection, for the treatment and prevention of autoimmune disease and of inflammatory conditions, and for the treatment of multi-drug resistance (MDR).

25 With regard to the treatment and prevention of organ or tissue transplant rejection, the compositions of the present invention containing cyclosporin are useful for the treatment of the recipients of heart, lung, combined heart-lung, liver, kidney, pancreatic, bone-marrow, skin or corneal transplants, and in particular allogenic transplants, for example. In addition, the compositions of the present invention are useful for the prevention of graft-versus-host-disease, which can sometimes be seen following bone marrow transplantation.

30

With regard to the treatment and prevention of autoimmune disease and of inflammatory conditions, the compositions of the present invention containing cyclosporin may be useful for the

treatment of autoimmune hematological disorder (including hemolytic anemia, aplastic anemia, pure red cell anemia and idiopathic thrombocytopenia), systemic lupus erythematosus, polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, idiopathic sprue, autoimmune
 5 inflammatory bowel disease (such as ulcerative colitis and Crohn's disease), endocrine ophthalmopathy, Graves disease, sarcoidosis, multiple sclerosis, primary billiary cirrhosis, juvenile diabetes (diabetes mellitus type I), uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis and glomerulonephritis (with and without nephrotic syndrome, such as idiopathic nephrotic syndrome or minimal change
 10 nephropathy).

In addition, these compositions may be particularly useful for inflammatory conditions with an etiology including an autoimmune component such as arthritis (for example, rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases.

With regard to multi-drug resistance (MDR), the compositions of the present invention
 15 containing cyclosporin may be useful for reversing or abrogating anti-neoplastic agent resistance in tumors and the like.

The following examples are illustrations only of methods of treating these disorders with
 the compositions of the present invention containing cyclosporin, and are not intended to be limiting.

20 The method includes the step of administering the composition of the present invention containing cyclosporin, as described in Example 18 above, to a subject to be treated. The composition of the present invention is administered according to an effective dosing methodology, preferably until a predefined endpoint is reached (if possible), such as the absence of symptoms of the disorder in the subject. For other disorders, such as organ or tissue transplant rejection, the
 25 composition of the present invention may need to be administered continuously without any endpoint.

Hereinafter, the term "treatment" includes both pretreatment, before a pathological condition has arisen, and treatment after the condition has arisen. The term "treating" includes both
 30 treating the subject after the pathological condition has arisen, and preventing the development of the pathological condition.

While the invention has been described with respect to a limited number of embodiments, it will be appreciated that many variations, modifications and other applications of the invention may be made.

WHAT IS CLAIMED IS:

1. A composition for administering a cyclosporin compound, the composition comprising:
 - (a) a dispersible concentrate characterized by being capable of forming, upon contact with an aqueous solution, particles of a size of less than about 100 nm, said dispersible concentrate comprising:
 - (i) at least one surfactant; and
 - (ii) a hydrophilic solvent characterized by being a lower alkyl ester of hydroxyalkanoic acid or an N-alkyl pyrrolidone; and
 - (b) a pharmaceutically effective amount of the cyclosporin compound.
2. The composition of claim 1, wherein said hydrophilic solvent includes a lower alkyl hydroxy alkanoic acid ester.
3. The composition of claim 2, wherein said lower alkyl hydroxy alkanoic acid ester includes ethyl lactate.
4. The composition of claim 1, wherein said hydrophilic solvent includes a lower alkyl N-alkyl pyrrolidone.
5. The composition of claim 4, wherein said lower alkyl N-alkyl pyrrolidone includes N-methyl pyrrolidone.
6. The composition of claim 1, wherein said hydrophilic solvent includes a combination of a lower alkyl ester of N-alkyl pyrrolidone and a lower alkyl hydroxy alkanoic acid ester.
7. The composition of claim 1, wherein said at least one surfactant is a combination of at least two surfactants, at least one surfactant of said combination being a high HLB (hydrophilic/lipophilic balance) surfactant having an HLB of at least about 8, and at least one surfactant of said combination being a low HLB surfactant having an HLB of less than about 5.

8. The composition of claim 7, wherein said combination is a combination of polyoxyethylene(20)sorbitan monolaurate and sorbitan monooleate.
9. The composition of claim 7, further comprising:
 - (c) an ethoxylated fat.
10. The composition of claim 9, wherein said ethoxylated fat is selected from the group consisting of polyethyleneglycol-hydrogenated castor oils.
11. The composition of claim 10, wherein said ethoxylated fat is selected from the group consisting of Cremophor™ EL, Cremophor™ RH 40 and Cremophor™ RH 60.
12. The composition of claim 9, further comprising:
 - (d) a phospholipid.
13. The composition of claim 12, wherein said phospholipid is selected from the group consisting of egg phospholipid and soy phospholipid.
14. The composition of claim 12, further comprising:
 - (e) a fatty acid ester.
15. The composition of claim 14, wherein said fatty acid ester is a solid fat at room temperature.
16. The composition of claim 15, wherein said fatty acid ester is tricaprln.
17. The composition of claim 1, wherein said particle size is less than about 60 nm.
18. The composition of claim 17, wherein said particle size is in a range of from about 5 nm to about 50 nm.

19. The composition of claim 1, wherein the cyclosporin compound is Ciclosporin.

20. A composition for administering a cyclosporin compound, the composition comprising a pharmaceutically effective amount of the composition of claim 1, and an aqueous solution as a diluent for said pharmaceutically effective amount of the composition of claim 1.

21. A composition for administering a cyclosporin compound, the composition comprising a lyophilized composition, said lyophilized composition being formed from a pharmaceutically effective amount of the composition of claim 1 and an aqueous solution as a diluent for said pharmaceutically effective amount of the composition of claim 1 to form a diluted solution, said diluted solution being lyophilized to form said lyophilized composition.

22. A method for administering a cyclosporin compound to a subject, the method comprising the step of administering a pharmaceutically effective amount of the composition of claim 1 to the subject.

23. The method of claim 22, wherein said pharmaceutically effective amount of the composition of claim 1 is administered to the subject through oral administration.

24. The method of claim 23, wherein said pharmaceutically effective amount of the composition of claim 1 is administered as a dispersion with an aqueous solution as a diluent.

25. A method for determining storage stability of a formulation containing a cyclosporin compound, the method comprising the step of analyzing the composition of claim 1 for particle size, such that if said particle size is less than about 100 nm, the formulation is determined to be stable.

26. A composition for administering a cyclosporin compound, the composition comprising:

- (a) a dispersible concentrate characterized by being capable of forming, upon contact with an aqueous solution, particles of a size of less than about 100 nm, said dispersible concentrate comprising:

- (i) an ethoxylated fat; and
 - (ii) a hydrophilic solvent characterized by being a lower alkyl ester of hydroxyalkanoic acid or an N-alkyl pyrrolidone; and
- (b) a pharmaceutically effective amount of the cyclosporin compound.

27. The composition of claim 26, wherein said ethoxylated fat is selected from the group consisting of polyethyleneglycol-hydrogenated castor oils.

28. The composition of claim 27, wherein said ethoxylated fat is selected from the group consisting of Cremophor™ EL, Cremophor™ RH 40 and Cremophor™ RH 60.

29. The composition of claim 26, wherein said hydrophilic solvent includes a lower alkyl hydroxy alkanoic acid ester.

30. The composition of claim 29, wherein said lower alkyl hydroxy alkanoic acid ester includes ethyl lactate.

31. The composition of claim 26, wherein said hydrophilic solvent includes a lower alkyl N-alkyl pyrrolidone.

32. The composition of claim 31, wherein said lower alkyl N-alkyl pyrrolidone includes N-methyl pyrrolidone.

33. The composition of claim 26, wherein said hydrophilic solvent includes a combination of a lower alkyl ester of N-alkyl pyrrolidone and a lower alkyl hydroxy alkanoic acid ester.




Figure 1




Figure 2





Figure 3



Docket No.
D01/166

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled
DISPERSIBLE CONCENTRATE FOR THE DELIVERY OF CYCLOSPORIN

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on _____ as United States Application No. or PCT International
Application Number _____
and was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			Priority Not Claimed
N/A			<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional

09/223,378

(Application Serial No.)

30 DEC 98

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

PCT/IL99/00710

(Application Serial No.)

30 DEC 99

(Filing Date)

PENDING

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

D'VORAH GRAESER

40,000

Send Correspondence to: DR. D. GRAESER LTD.
C/O THE POLKINGHORNS
9003 FLORIN WAY
UPPER MARLBORO, MD. 20772, USA

Direct Telephone Calls to: (name and telephone number)
THE POLKINGHORNS: 301-952-1011

Full name of sole or first inventor <u>ABRAHAM DOMB</u>	
Sole or first inventor's signature <u>X Abraham J. Domb</u>	Date <u>10.9.2001</u>
Residence <u>16 MIGDAL EDER STREET, EFRAT 90436, ISRAEL ILX</u>	
Citizenship <u>ISRAEL</u>	
Post Office Address <u>16 MIGDAL EDER STREET, EFRAT 90436, ISRAEL</u>	

Full name of second inventor, if any	
Second inventor's signature	Date
Residence	
Citizenship	
Post Office Address	